H
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
H. Terence Cook's research focuses on the role of the complement system in kidney diseases, particularly IgA nephropathy and C3 glomerulopathy. His work investigates the clinical outcomes and histological parameters associated with these conditions, exploring the impact of rare kidney diseases on kidney failure through longitudinal analysis of national registry data. Cook has also examined the effects of specific therapeutic agents, such as the factor D inhibitor danicopan, on patients with C3 glomerulopathy and idiopathic immunoglobulin-associated membranoproliferative glomerulonephritis.
His research extends to understanding the nomenclature and diagnostic criteria for atypical hemolytic uremic syndrome, contributing to a roadmap for precision in its identification. Cook's collaborations include work with Rupak Pathak, Enoch K. Larrey, Edith Nathalie Pineda, and Igor Koturbash, all at the University of Arkansas for Medical Sciences. With an h-index of 60 and over 16,130 citations across 168 publications, Cook is recognized as a highly cited researcher.
Metrics
- h-index: 60
- Publications: 168
- Citations: 16,272
Selected Publications
-
Geranylgeranyl Transferase Inhibitors Mitigate Intestinal Radiation Toxicity (2025)
-
Sex-specific immune alterations in mice following long-term simulated microgravity and chronic irradiation (2025)
Collaboration Network
Top Collaborators
Matthew C. Pickering
Imperial College London (GB)
11 shared publications
- Complement activation in IgA nephropathy
- The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Showing 5 of 11 shared publications
Bradley P. Dixon
University of Colorado Denver (US)
5 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
- POS-047 PHASE 2 STUDY TO EVALUATE EFFICACY AND SAFETY OF PEGCETACOPLAN IN THE TREATMENT OF PATIENTS WITH POSTTRANSPLANT RECURRENCE OF C3G OR IC MPGN
- Biomarkers in the Management of Complement-Mediated Kidney Diseases in the Era of Complement Therapeutics
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research (IT)
5 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
- Clinical and Histological Predictors of Outcomes in C3 Glomerulopathy
Hannah J. Lomax-Browne
Imperial College London (GB)
4 shared publications
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- Gain-of-function factor H–related 5 protein impairs glomerular complement regulation resulting in kidney damage
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
- Clinical and Histological Predictors of Outcomes in C3 Glomerulopathy
Nicholas Medjeral‐Thomas
GlaxoSmithKline (United Kingdom) (GB)
4 shared publications
- Complement activation in IgA nephropathy
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- Complement and kidney disease, new insights
- Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes
Erica Daina
Mario Negri Institute for Pharmacological Research (IT)
4 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
- Clinical and Histological Predictors of Outcomes in C3 Glomerulopathy
David Kavanagh
Royal Victoria Infirmary (GB)
4 shared publications
- Effects of rare kidney diseases on kidney failure: a longitudinal analysis of the UK National Registry of Rare Kidney Diseases (RaDaR) cohort
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Description and Cross-Sectional Analyses of 25,880 Adults and Children in the UK National Registry of Rare Kidney Diseases Cohort
- Kidney Complement Immunohistochemistry in Thrombotic Microangiopathy Subtypes
Marina Noris
Mario Negri Institute for Pharmacological Research (IT)
4 shared publications
- The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
- Clinical and Histological Predictors of Outcomes in C3 Glomerulopathy
Sean J. Barbour
BC Cancer Agency (CA)
3 shared publications
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN
Andrew S. Bomback
Columbia University Irving Medical Center (US)
3 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Gerald B. Appel
Columbia University Irving Medical Center (US)
3 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Ingeborg M. Bajema
University Medical Center Groningen (NL)
3 shared publications
- The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- #2683 Characterizing the NIH activity and chronicity indices in two independent lupus nephritis cohorts: a critical analysis
Fádi Fakhouri
University of Lausanne (CH)
3 shared publications
- The role of complement in kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference
- Association of Histologic Parameters with Outcome in C3 Glomerulopathy and Idiopathic Immunoglobulin-Associated Membranoproliferative Glomerulonephritis
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
C. John Sperati
Johns Hopkins University (US)
3 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Carla Nester
University of Iowa Stead Family Children’s Hospital (US)
3 shared publications
- Clinical Outcomes of Patients with C3G or IC-MPGN Treated with the Factor D Inhibitor Danicopan: Final Results from Two Phase 2 Studies
- An expert discussion on the atypical hemolytic uremic syndrome nomenclature—identifying a road map to precision: a report of a National Kidney Foundation Working Group
- Baseline Clinical Characteristics and Complement Biomarkers of Patients with C3 Glomerulopathy Enrolled in Two Phase 2 Studies Investigating the Factor D Inhibitor Danicopan
Similar Researchers
Based on overlapping research topics
R. DALEY GOFF
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Dialysis and Renal Disease Management
Metabolism and Genetic Disorders
Ninad Khandekar
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Immune Response and Inflammation
Dialysis and Renal Disease Management
Hannah Barkley
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Metabolism and Genetic Disorders
Genomics and Rare Diseases
Breanna Greaves
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Immune Response and Inflammation
Medical Case Studies
Nayef Alshammari
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Metabolism and Genetic Disorders
Health Disparities and Outcomes
Matthew R. Savage
University of Arkansas for Medical Sciences
Disease Mechanisms Research
Immune Response and Inflammation
Metabolism and Genetic Disorders